Trial Profile

Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer: a Multi-center Phase Ib/II Study

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 27 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dalpiciclib (Primary) ; Fulvestrant (Primary) ; Letrozole (Primary) ; Pyrotinib (Primary)
Indications Advanced breast cancer; HER2 positive breast cancer
Focus Adverse reactions; Therapeutic Use
Acronyms PLEASURABLE

Most Recent Events

06 Jun 2023 Results (As of January 19, 2023, n=48) presented at the 59th Annual Meeting of the American Society of Clinical Oncology
05 Mar 2023 Planned End Date changed from 12 Dec 2022 to 10 Dec 2025.
05 Mar 2023 Planned primary completion date changed from 12 Jun 2020 to 10 Jun 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com